---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-23-000034"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T15:28:54.238013+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LianBio reports FY2022 net loss of $110.3M; cash $302.4M with runway through end of 2024

## Summary
- Net loss $18.3M in Q4 2022 ($21.2M in Q4 2021); FY2022 loss $110.3M vs $196.3M in 2021.
- Cash, cash equivalents and marketable securities $302.4M at Dec 31, 2022, down $100.8M from 2021.
- Phase 3 EXPLORER-CN trial of mavacamten completed patient visits; topline data expected mid-2023.
- Entered commercial agreement with Pfizer for sisunatovir; received $20M upfront, eligible for up to $135M milestones.
- Phase 3 LIBRA trial of TP-03 for Demodex blepharitis ongoing; data expected Q4 2023.

## SEC filing metadata
- accession: 0001831283-23-000034
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000034/0001831283-23-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000034/lian-20230327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-23-000034
- JSON: https://secwatch.observer/filing/0001831283-23-000034.json
- Plain text: https://secwatch.observer/filing/0001831283-23-000034.txt

## Key facts
- Earnings Releases
  LianBio reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On March 27, 2023, LianBio issued a press release announcing its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000034/0001831283-23-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.